Skip to main content
Equibles
HAE logo

HAE · Haemonetics Corp · Earnings Call Transcripts & Audio

Track HAE — free

Use HAE with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research HAE.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$102.69 +1.63 (+1.61%) At close · Sep 11
S&P 400 member Russell 2000 member Rebalance outlook locked
Market Cap
$4.67B
Shares
45.50M

Haemonetics Corp Earnings Call Transcripts

Quarterly earnings calls for Haemonetics Corp (HAE), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲24% $297.49M $33.20M '23 Q2 22-11-07 ▲17.5% $305.30M $32.94M '23 Q3 23-02-07 ▲14.9% $304.42M $29.38M '23 Q4 23-05-11 ▲19.1% $311.33M $41.04M '24 Q1 23-08-08 ▲7% $318.18M $24.91M '24 Q2 23-11-02 ▲10.1% $336.25M $31.24M '24 Q3 24-02-08 ▲12.8% $343.29M $20.37M '24 Q4 24-05-09 ▲8% $336.17M $38.37M '25 Q1 24-08-08 ▲8.6% $345.51M $33.83M '25 Q2 24-11-07 ▲3.7% $348.54M $37.49M '25 Q3 25-02-06 ▼3.7% $330.60M $57.98M '25 Q4 25-05-08 ▼4.4% $321.39M $34.03M '26 Q1 25-08-07 ▼5.3% $327.31M $38.68M '26 Q2 25-11-06 ▼2.7% $338.97M $44.74M '26 Q3 26-02-05 ▲4.8% $346.35M −$20.15M '26 Q4 26-05-07 LATEST ▲5.6% $339.38M $33.01M '27 Q1 26-08-06
Conference
Investor event
2026-09-22
Haemonetics Corp (HAE) September 2026 Conference
Scheduled
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-09-15
Haemonetics Corp (HAE) September 2026 Conference
Scheduled
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY27 · Q1
2026-08-06
Haemonetics Corp (HAE) Q1 2027 Earnings Call Transcript
Confident tone Plasma franchise and Persona Plus adoption Board addition and governance refresh Hospital capital equipment environment / TEG
Revenue
$339.38M
▲ 5.6% YoY
Diluted EPS
$0.72
▲ 2.9% YoY
Gross margin
59.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q4
2026-05-07
Haemonetics Corp (HAE) Q4 2026 Earnings Call Transcript
Positive tone Plasma business momentum and guidance Margin expansion and cash flow Guidance assumptions and conservatism on volume
Revenue
$346.35M*
▲ 4.8% YoY
Gross margin
57.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY26 · Q3
2026-02-05
Haemonetics Corp (HAE) Q3 2026 Earnings Call Transcript
Confident tone Plasma franchise momentum Interventional Technologies / vascular closure turnaround Margin expansion and free cash flow
Revenue
$338.97M
▼ 2.7% YoY
Diluted EPS
$0.95
▲ 28.4% YoY
Gross margin
59.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q2
2025-11-06
Haemonetics Corp (HAE) Q2 2026 Earnings Call Transcript
Confident tone Plasma business strength FY26 guidance raise Interventional Technologies / Vascular Closure turnaround
Revenue
$327.31M
▼ 5.3% YoY
Diluted EPS
$0.81
▲ 22.7% YoY
Gross margin
59.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2025-08-07
Haemonetics Corp (HAE) Q1 2026 Earnings Call Transcript
Positive tone Plasma / NexSys Performance Blood Management Technologies / TEG Guidance Reaffirmation and Long-Range Plan
Revenue
$321.39M
▼ 4.4% YoY
Diluted EPS
$0.70
▼ 5.4% YoY
Gross margin
59.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2025-05-08
Haemonetics Corp (HAE) Q4 2025 Earnings Call Transcript
Positive tone Plasma and CSL Transition Hospital Business Growth Capital Allocation and Share Buyback
Revenue
$330.60M*
▼ 3.7% YoY
Gross margin
58.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-02-06
Haemonetics Corp (HAE) Q3 2025 Earnings Call Transcript
Confident tone Hospital segment growth Whole blood divestiture and portfolio rationalization Plasma business and CSL transition
Revenue
$348.54M
▲ 3.7% YoY
Diluted EPS
$0.74
▲ 21.3% YoY
Gross margin
55.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2024-11-07
Haemonetics Corp (HAE) Q2 2025 Earnings Call Transcript
Positive tone Plasma business and CSL transition Guidance and outlook Blood Management Technologies (TEG)
Revenue
$345.51M
▲ 8.6% YoY
Diluted EPS
$0.66
▲ 37.5% YoY
Gross margin
54.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2024-08-08
Haemonetics Corp (HAE) Q1 2025 Earnings Call Transcript
Positive tone Hospital / interventional technologies growth International expansion (Japan and Europe) Geopolitical and China headwinds
Revenue
$336.17M
▲ 8% YoY
Diluted EPS
$0.74
▼ 7.5% YoY
Gross margin
52.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2024-05-09
Haemonetics Corp (HAE) Q4 2024 Earnings Call Transcript
Confident tone FY2025 guidance and CSL headwind Plasma business and Express Plus rollout Acquisitions (OpSens and Attune)
Revenue
$343.29M*
▲ 12.8% YoY
Gross margin
51.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-02-08
Haemonetics Corp (HAE) Q3 2024 Earnings Call Transcript
Confident tone Hospital segment momentum Plasma franchise growth OpSens acquisition and integration
Revenue
$336.25M
▲ 10.1% YoY
Diluted EPS
$0.61
▼ 4.7% YoY
Gross margin
52.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2023-11-02
Haemonetics Corp (HAE) Q2 2024 Earnings Call Transcript
Revenue
$318.18M
▲ 7% YoY
Diluted EPS
$0.48
▼ 25% YoY
Gross margin
53.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2023-08-08
Haemonetics Corp (HAE) Q1 2024 Earnings Call Transcript
Revenue
$311.33M
▲ 19.1% YoY
Diluted EPS
$0.80
▲ 110.5% YoY
Gross margin
53.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2023-05-11
Haemonetics Corp (HAE) Q4 2023 Earnings Call Transcript
Revenue
$304.42M*
▲ 14.9% YoY
Gross margin
51.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-02-07
Haemonetics Corp (HAE) Q3 2023 Earnings Call Transcript
Revenue
$305.30M
▲ 17.5% YoY
Diluted EPS
$0.64
▲ 42.2% YoY
Gross margin
52.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2022-11-07
Haemonetics Corp (HAE) Q2 2023 Earnings Call Transcript
Revenue
$297.49M
▲ 24% YoY
Diluted EPS
$0.64
▲ 120.7% YoY
Gross margin
53.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2022-08-10
Haemonetics Corp (HAE) Q1 2023 Earnings Call Transcript
Revenue
$261.46M
▲ 14.4% YoY
Diluted EPS
$0.38
Gross margin
54.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2022-05-10
Haemonetics Corp (HAE) Q4 2022 Earnings Call Transcript
Revenue
$265.00M*
▲ 17.8% YoY
Gross margin
51.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-02-08
Haemonetics Corp (HAE) Q3 2022 Earnings Call Transcript
Revenue
$259.77M
▲ 8.1% YoY
Diluted EPS
$0.45
▼ 27.4% YoY
Gross margin
53.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2021-11-09
Haemonetics Corp (HAE) Q2 2022 Earnings Call Transcript
Revenue
$239.90M
▲ 14.5% YoY
Diluted EPS
$0.29
▼ 69.1% YoY
Gross margin
51.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2021-08-11
Haemonetics Corp (HAE) Q1 2022 Earnings Call Transcript
Revenue
$228.53M
▲ 16.8% YoY
Diluted EPS
$-0.09
▼ 142.9% YoY
Gross margin
47.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2021-05-13
Haemonetics Corp (HAE) Q4 2021 Earnings Call Transcript
Revenue
$225.03M
▼ 5.6% YoY
Diluted EPS
$-0.22
▼ 164.7% YoY
Gross margin
36.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-02-02
Haemonetics Corp (HAE) Q3 2021 Earnings Call Transcript
Revenue
$240.37M
▼ 7.2% YoY
Diluted EPS
$0.62
▲ 6.9% YoY
Gross margin
50.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2020-11-04
Haemonetics Corp (HAE) Q2 2021 Earnings Call Transcript
Revenue
$209.49M
▼ 17.1% YoY
Diluted EPS
$0.94
▲ 30.6% YoY
Gross margin
50.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2020-06-30
Haemonetics Corp (HAE) Q1 2021 Earnings Call Transcript
Revenue
$195.58M
▼ 18% YoY
Diluted EPS
$0.21
Gross margin
46.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2020-05-05
Haemonetics Corp (HAE) Q4 2020 Earnings Call Transcript
Revenue
$238.49M
▼ 4.3% YoY
Diluted EPS
$0.34
▼ 15% YoY
Gross margin
47.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-02-04
Haemonetics Corp (HAE) Q3 2020 Earnings Call Transcript
Revenue
$258.97M
▲ 4.7% YoY
Diluted EPS
$0.58
▲ 65.7% YoY
Gross margin
49.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2019-06-30
Haemonetics Corp (HAE) Q1 2020 Earnings Call Transcript
Revenue
$238.45M
▲ 4% YoY
Diluted EPS
$-0.17
Gross margin
48.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–30 of 30 earnings calls
Key facts CIK 313143 CUSIP 405024100 13F (30d) 92 filings 92 filers Visit website Investor relations